This clinical trial is focused on the long-term follow-up of participants who have been previously treated for Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The treatment being studied is called Ciltacabtagene Autoleucel, also known by its code name JNJ-68284528. This treatment is a form of cell therapy where a patient’s own T-cells, a type of immune cell, are genetically modified to better recognize and attack cancer cells. The modified cells are then infused back into the patient.

The purpose of this study is to gather information on any delayed side effects that may occur after receiving Ciltacabtagene Autoleucel and to understand its long-term safety. Participants in this study have already received this treatment in a previous clinical trial. The study will monitor for any new or worsening health issues, such as new cancers, neurological disorders, or autoimmune conditions, over an extended period. It will also track the overall survival of participants and the long-term effectiveness of the therapy.

Throughout the study, participants will have regular check-ups to assess their health and any potential side effects. The study aims to provide valuable insights into the long-term impact of this innovative treatment for Multiple Myeloma, helping to ensure its safety and effectiveness for future patients. The study is expected to continue for several years to gather comprehensive data on the participants’ health outcomes.